CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 1,150 enrolled
Drug / intervention
interferon alfa-2b +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00003641
NCT00003641Phase 3Active
CompareCT.gov

Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma

ECOG-ACRIN Cancer Research Group·interventional·Posted Jan 27, 2003·Updated Feb 25, 2026

In Brief

A Phase 3 clinical trial evaluating interferon alfa-2b and observation for Melanoma (Skin). Active but no longer recruiting, targeting 1,150 participants across 533 sites in 4 countries.

Detailed Summary

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma (Skin)
CountriesAustralia, Canada, South Africa, United States
CollaboratorsNational Cancer Institute (NCI), SWOG Cancer Research Network, Cancer and Leukemia Group B, NCIC Clinical Trials Group, Children's Oncology Group

Timeline

Phase 3Active
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartMar 25, 1999
Primary CompletionJan 1, 2015
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 15.8 yearsPosted 23.4 years ago

Interventions

interferon alfa-2bbiological

Given IV

observationother

Patients undergo observation for 4 weeks.